Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Etrasimod→

Etrasimod Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1206123-37-6
Molecular formula
C26H26F3NO3
Molecular weight
457.5 g/mol
Drug class
Selective sphingosine 1-phosphate (S1P) receptor modulatorimmunomodulatory agent
Mechanism of action
Binds S1P receptor subtypes 1, 4 and 5, with functional antagonism at S1P1 that reduces lymphocyte egress from lymph nodes and circulating lymphocyte counts, limiting lymphocyte migration to inflamed intestinal tissue.
Indications / reported uses
  • Treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response, loss of response or intolerance to conventional therapy or a biologic agent, under the applicable product label

Sources: US DailyMed — VELSIPITY (etrasimod) · EMA EPAR — Velsipity · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Etrasimod Environmental Risk Assessment (ERA) (the Etrasimod ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.